Tributary Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Tributary Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16,000	Closed	-$767K	–	224
2020 Q2	$767K	Sell	16,000 -600	-4%	-$46.4K	0.07%	148
2020 Q1	$1.04M	Buy	16,600 +4,210	+34%	+$378K	0.11%	118
2019 Q4	$1.53M	Buy	12,390 +6,790	+121%	+$608K	0.11%	119
2019 Q3	$372K	Sell	5,600 -7,000	-56%	-$470K	0.03%	190
2019 Q2	$1M	Sell	12,600 -800	-6%	-$71.6K	0.07%	142
2019 Q1	$1.5M	Hold	13,400	–	–	0.11%	118
2018 Q4	$1.35M	Buy	13,400 +1,400	+12%	+$145K	0.12%	115
2018 Q3	$1.52M	Buy	12,000 +3,000	+33%	+$317K	0.12%	127
2018 Q2	$755K	Buy	+9,000	New	+$659K	0.06%	152

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Tributary Capital Management's ICPT Position: Q3 2020 in Review

Tributary Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 16,000 shares — an estimated $767K sold.

Tributary Capital Management first reported a position in ICPT in Q2 2018 and held it in 9 quarters. The position peaked at $1.53M in Q4 2019. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

Tributary Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Tributary Capital Management sold 16,000 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $767K.
Tributary Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 9 quarters.
Tributary Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.53M in Q4 2019.
177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Tributary Capital Management's 13F filing for Q3 2020, filed 13 Oct 2020.